Skip to content
Screener

Neuropace, Inc. NPCE Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

ClearPoint Neuro logo
ClearPoint NeuroCLPT
$9.16M+157%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$11.48M+678%
CVRx, Inc. logo
CVRx, Inc.CVRX
$819K-28.9%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$6.42M-26.4%
Neuronetics logo
NeuroneticsSTIM
$25M-0.5%
VAN
Vivani MedicalVANI
$18.28M-3.5%

Other financials

Income statement

See full
Revenue$22.8M+17.1%
Gross profit$18.9M+16.6%
Operating income-$5.1M+37.2%
Net income-$6.2M+28.3%
EPS (diluted)-$0.18+30.8%

Balance sheet

See full
Cash & equivalents$12.8M-44.4%
Total debt$69.9M-2.2%
Total equity$11.9M-38.9%
Total assets$97.0M-8.6%

Cash flow

See full
Operating cash flow-$3.9M-87.1%
CapEx$125.0K-25.6%
Free cash flow-$4.0M-78.7%

Valuation

See full
Market cap$505.61M+73.4%
Enterprise value$562.76M+65.5%
P/S5.1×+1.7×

Profitability

See full
Gross margin79.6%+2.6pp
Operating margin-15.3%-4.3pp
Net margin-19.3%-5.2pp
FCF margin-12.2%-3.3pp

Returns & leverage

See full
Return on equity-122.1%-28.9pp
Debt / equity5.9×+2.2×
Current ratio4.9×-0.5×

Where this comes from

Reported directly by Neuropace, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.

The source filing: Neuropace, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 4:33 PM EDT
Fiscal quarter
Q4 FY2030
Calendar quarter
Q4 2030
Accession
0001528287-26-000030
(in thousands)June 30,2026June 30,2026
20283,215
20293,312
20301,704
Total undiscounted lease payments12,868
Less: imputed interest1,951
Total operating lease liability10,917
Less: current portion2,256
Operating lease liability, net of current portion$$8,661

Item 1. Financial Statements (Unaudited)

FAQ

What is Neuropace, Inc.'s operating lease liabilities (total)?
Neuropace, Inc. (NPCE) reported operating lease liabilities (total) of $10.92M in Q2 2026.
How has Neuropace, Inc.'s operating lease liabilities (total) changed year-over-year?
Neuropace, Inc.'s operating lease liabilities (total) decreased by 15.4% year-over-year, from $12.9M to $10.92M.
What is the long-term trend for Neuropace, Inc.'s operating lease liabilities (total)?
Over 4 years (2021 to 2025), Neuropace, Inc.'s operating lease liabilities (total) has grown at a 12.4% compound annual growth rate (CAGR), from $7.5M to $11.95M.
What does operating lease liabilities (total) mean?
This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.

Ask your AI about Neuropace, Inc.'s operating lease liabilities (total).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude